The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.50
Bid: 65.00
Ask: 70.00
Change: 1.00 (1.50%)
Spread: 5.00 (7.692%)
Open: 66.50
High: 67.50
Low: 66.50
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Termination of Formal Sales Process

15 Jan 2019 11:08

RNS Number : 1482N
NetScientific PLC
15 January 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

FOR IMMEDIATE RELEASE

15 January 2019

NetScientific plc

("NetScientific" or the "Company")

Termination of Formal Sales Process

 

On 20 December 2018, NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation group, announced, inter alia, that, following its decision to conduct a review of various strategic options open to it, announced on 26 November 2018, (the "Strategic Review"), it was not in receipt of any approaches, and that it was not then in discussions with any potential offeror concerning a sale of the Company.

This remains the case and the Board is not aware of any parties who might now make such an approach or initiate such discussions.

Accordingly, the Company confirms that it has closed the formal sale process under the City Code on Takeovers and Mergers (the "Takeover Code") that it had commenced as part of the Strategic Review.

Following this announcement, the Company is no longer considered to be in an "offer period" as defined in the Takeover Code and the requirement to make disclosures under Rule 8 of the Takeover Code has now ceased.

In light of the above, the Board continues to assess all of its remaining strategic options, including seeking additional funding from its shareholders and taking material action to reduce further the Company's costs, which may include seeking a delisting.

Further announcements will be made as appropriate.

For more information, please contact:

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave / Chris Viggor

 

Tel: +44 (0)20 7220 1666

 

Ondra (Financial Adviser)

Michael Tory / Michiel Bröker

 

Tel: +44 (0)20 7082 8827

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

NetScientific@consilium-comms.com

Tel: +44 (0)20 3709 5700

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

Important notices

Ondra LLP, which is regulated in the United Kingdom by the Financial Conduct Authority, is acting as joint financial adviser exclusively for NetScientific and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of Ondra LLP, nor for providing advice in relation to any matter referred to herein.

This announcement has been prepared by, and is the sole responsibility of the Directors of NetScientific. WH Ireland Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for NetScientific and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of WH Ireland Limited., or for providing advice in relation to the matters referred to in this announcement.

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Cautionary note regarding forward-looking statements

This announcement may contain certain forward-looking statements, beliefs or opinions, with respect to the financial condition, results of operations, financial performance, business strategy or plans for future operations the Company. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "hope", "aims", "continue", "will", "may", "should", "would", "could", or other words of similar meaning. These statements are based on assumptions and assessments made by the Company in light of their experience and their perception of historical trends, current conditions, future developments and other factors they believe appropriate.

By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this announcement could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement.

The Company does not assume any obligation to, and does not intend to, update or correct the information contained in this announcement (whether as a result of new information, future events or otherwise), except as required by applicable law. There are several factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax rates and future business combinations or disposals.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDKDBKDPDD
Date   Source Headline
27th May 20214:36 pmRNSPrice Monitoring Extension
24th May 20217:00 amRNSProAxsis Update
21st May 202111:00 amRNSPrice Monitoring Extension
20th May 20214:19 pmRNSPDS Announces Release of PDS0101 Abstract
20th May 20217:00 amRNSEMV Capital Advises on £3.4m PointGrab Fundraise
18th May 20217:00 amRNSPDS receives $4.5m from net sale of tax benefits
13th May 20213:15 pmRNSPDS Reports Results for Q1 2021 & Business Update
13th May 20217:00 amRNSEMV Capital Advises on £2.9m SageTech Fundraise
30th Apr 20217:00 amRNSPDS Announces Presentation at ASCO Annual Meeting
28th Apr 202110:08 amRNSEMV Capital Advises on £740k Fundraise for Sofant
14th Apr 20212:25 pmRNSNotice of AGM and Annual Report & Accounts
31st Mar 20219:02 amRNSPreliminary Results for the year ended 31 Dec 2020
30th Mar 20217:00 amRNSNotice of Results & Investor Presentation
18th Mar 202111:48 amRNSPDS Reports Results for FY2020 & Business Update
11th Mar 20213:26 pmRNS$60m Commitment for PDS Vaccine Consortium
23rd Feb 20217:00 amRNSPDS Biotech Consortium Update
22nd Feb 20217:00 amRNSProAxsis Update
10th Feb 202111:01 amRNSPrice Monitoring Extension
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
5th Feb 20212:06 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 202111:05 amRNSSecond Price Monitoring Extn
5th Feb 202111:00 amRNSPrice Monitoring Extension
3rd Feb 20212:45 pmRNSRestoration - Netscientific plc
3rd Feb 20212:45 pmRNSPDS Phase II Trial Update & Restoration of Trading
2nd Feb 20217:30 amRNSSuspension - Netscientific plc
2nd Feb 20217:00 amRNSSuspension of Trading on AIM
25th Jan 20217:00 amRNSIssue of Shares, Director/PDMR Shareholding & TVR
4th Jan 202110:31 amRNSHolding(s) in Company
21st Dec 20202:59 pmRNSPDS Announces Publication of Data by Mount Sinai
10th Dec 20207:00 amRNSProAxsis awarded Innovate UK grant
7th Dec 202011:05 amRNSSecond Price Monitoring Extn
7th Dec 202011:00 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSBoard changes and Grant of Options
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.